Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
<i>Background</i>: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in <i>EGFR</i> mutant non-small cell lung cancer (NSCLC), where target therapy is moving to early stages. In the current review, we collected the available data exp...
Main Authors: | Lorenzo Belluomini, Silvia Teresa Riva, Michele Simbolo, Riccardo Nocini, Ilaria Trestini, Alice Avancini, Daniela Tregnago, Miriam Grazia Ferrara, Alberto Caldart, Alessandra Dodi, Anna Caliò, Emilio Bria, Aldo Scarpa, Michele Milella, Jessica Menis, Sara Pilotto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/10/2685 |
Similar Items
-
Implementation outcomes of early nutritional screening and referral for patients with thoracic cancers
by: Lorenzo Belluomini, et al.
Published: (2024-06-01) -
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
by: Zhang SS, et al.
Published: (2022-04-01) -
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
by: Lorenzo Belluomini, et al.
Published: (2020-12-01) -
Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Gengwei Huo, et al.
Published: (2024-03-01) -
Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
by: Marco Sposito, et al.
Published: (2023-09-01)